Search results
Results from the WOW.Com Content Network
In 1988, the "Oryx" project at IBM, under the technical direction of Simon C. Nash, experimented with merging classic Rexx with the object model of Smalltalk. [3] [4] The motivation behind the project was to transfer the advantages of OOP to classic Rexx while remaining compatible and thus transferring the usability of classic Rexx to OOP. [5]
Pfizer bought Oxbryta, also known as voxelotor, as part of its $5.4 billion buyout of Global Blood Therapeutics in 2022. Pfizer is also discontinuing all studies and access programs related to the ...
In numerical analysis and computational statistics, rejection sampling is a basic technique used to generate observations from a distribution.It is also commonly called the acceptance-rejection method or "accept-reject algorithm" and is a type of exact simulation method.
Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said. Oxbryta ...
The rate of return on a portfolio can be calculated indirectly as the weighted average rate of return on the various assets within the portfolio. [3] The weights are proportional to the value of the assets within the portfolio, to take into account what portion of the portfolio each individual return represents in calculating the contribution of that asset to the return on the portfolio.
Sennacherib's Annals are the annals of Sennacherib, emperor of the Neo-Assyrian Empire.They are found inscribed on several artifacts, and the final versions were found in three clay prisms inscribed with the same text: the Taylor Prism is in the British Museum, the ISAC or Chicago Prism in the Institute for the Study of Ancient Cultures and the Jerusalem Prism is in the Israel Museum in Jerusalem.
Tumor cells that are resistant to anti-mitogens allow the cell cycle to move forward when it should be prevented by some anti-mitogenic mechanism. This resistance to anti-mitogens might simply arise from overstimulation by positive mitogens. In other cases, tumor cells possess loss-of-function mutations in some part of the anti-mitogenic pathway.
At the time of its withdrawal, rofecoxib was the only coxib approved in the United States with clinical evidence of its superior gastrointestinal adverse effect profile over conventional NSAIDs. This was largely based on the VIGOR (Vioxx GI Outcomes Research) study, which compared the efficacy and adverse effect profiles of rofecoxib and naproxen .